TGF-β Concentration in Breast Milk is Associated With the Development of Eczema in Infants

Yoshinori Morita 1*, Eduardo Campos-Alberto 1, Fumiya Yamaide 1, Taiji Nakano 1, Hidenori Ohnisi 2, Minako Kawamoto 2, Norio Kawamoto 2, Eiko Matsui 2, Naomi Kondo 2, Yoichi Kohno 1 and Naoki Shimojo 1

*Correspondence: Yoshinori Morita
m0ritan@hotmail.com

1 Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan, 2 Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan

Background: Transforming growth factor (TGF)-β in breast milk is crucial for mucosal immune system in the neonatal period. We hypothesized that the level of exposure to TGF-β from breast milk in the first month of life is related to the development of eczema later in life. Thus, the present study investigated whether changes in TGF-β levels between colostrum and mature milk are associated with such occurrence in a birth cohort study.

Methods: Colostrum and 1-month breast milk samples were collected from mothers who participated in our birth cohort study. TGF-β1 and TGF-β2 levels in breast milk were measured using a commercial ELISA kit. The development of eczema in the first 6 months after birth was assessed based on parent’s response to a questionnaire. Levels of TGF-β1 and TGF-β2 were compared in breast milk from mothers of infants with and without eczema.

Results: In children with eczema, TGF-β1 levels were higher in colostrum, but lower in 1-month milk. A lower TGF-β1 ratio (1-month milk/colostrum) was related to the development of eczema during the first 6 months of life. There was no difference in TGF-β2 ratio (1-month milk/colostrum) between eczema group and control group.

Conclusions: Concentration of TGF-β1 but not TGF-β2 in breast milk during the first month after birth may be associated with eczema later in life. Factors that increase TGF-β1 levels in breast milk may play a role in preventing allergic disease.

Keywords: TGF-β, breast milk, infants, allergy, eczema

INTRODUCTION

Breast milk contains a wide variety of immune mediators, such as secretory immunoglobulin A, soluble CD14, and transforming growth factor (TGF)-β (1). These mediators are crucial for mucosal immune system in the neonatal period.

TGF-β may play a role in preventing allergic diseases. In animal models, the oral administration of TGF-β1 maintained the biological activity in the intestinal mucosa and enhanced the induction of oral tolerance (2). It has also been reported to inhibit inflammation in the intestinal epithelium and systemic production of interleukin-6 and interferon-γ, reducing the incidence of
necrotizing enterocolitis (NEC) (3). In contrast, developmental defects rather than immunological dysregulation were observed in TGF-β2- and TGF-β3-deficient mice (4, 5).

Several studies have been conducted to address whether the levels of TGF-β in breast milk are related to the development of allergic diseases. Although a review article reported TGF-β in breast milk is an effective cytokine in preventing allergic disease (6), the results of several other studies were controversial (7–9). Hence, we hypothesized that the amount of TGF-β received in the first month of life is important in the prevention of allergy, and in the present study we investigated whether changes in the TGF-β cytokine level in breast milk from colostrum to mature milk were related to the future development of eczema in infants.

MATERIALS AND METHODS

Study Design
This study is part of a birth cohort study of 500 newborn infants, which was conducted in Kawatetsu-Chiba Hospital from January 2007 to May 2008. The study design has been described in detail elsewhere (10). Briefly, all participants received a questionnaire when their infants were born. Data on parental allergic disease and various exposures were obtained. The parents also answered questionnaires on symptoms related to eczema in their infant at 1, 4, and 6 months of age. Eczema was defined as itchy skin rashes lasting >2 months in 6-month-old children.

Infants who presented with eczema at 6 months were included in the eczema group. As for the control group, we randomly selected infants who did not have eczema at 6 months. Both groups were matched in terms of feeding methods and history of atopic dermatitis or other allergic diseases in the mother (asthma, allergic rhinitis, food allergy, and pollen hypersensitivity). Levels of TGF-β1 and TGF-β2 in breast milk were measured in both groups.

The study protocol was approved by the Ethics Committee of Chiba University Graduate School of Medicine (No. 570). All parents provided written informed consent.

Breast Milk Collection and Processing of Breast Milk
Colostrum samples were collected within 5 days post-partum and mature milk samples were collected 1 month after delivery. Each sample was frozen within 12 h of collection and kept at −80°C. After thawing, the samples were centrifuged at 10,000 g for 10 min, the cellular debris and fat layer were discarded, and the clear middle layer was used for analyses.

Measurements of TGF-β1 and TGF-β2 in Breast Milk
TGF-β1 and TGF-β2 levels in breast milk were measured with the Quantikine Human TGF-β1 and TGF-β2 Immunoassays (R&D Systems Inc, MN, USA). Activation of TGF-β in breast milk was performed using 1N HCl and neutralized with 1N NaOH. The sensitivity threshold for both the TGF-β1 and TGF-β2 assays were 31.25 pg/mL. TGF-β1 levels below 31.25 pg/mL were also measured since we could confirm linearity with sequential dilution down to 1.95 pg/mL. We therefore defined 3.9 pg/mL as the detection limit of the TGF-β1 assay in this study. Since the clear middle layer was diluted 40 times in the neutralization step for TGF-β1 analysis, 156 pg/mL was defined as the detection limit. Undetectable levels of TGF-β1 were set as half the value of the minimum detectable level at 78 pg/mL. The clear middle layer was diluted 7.8 times in the neutralization step for TGF-β2 analysis, 243.75 pg/mL was defined as the detection limit. Undetectable levels of TGF-β2 were set as half the value of the minimum detectable level at 121.9 pg/mL.

Statistical Analysis
Differences in the characteristics of the participants were assessed by using chi-squared test or Fisher’s exact test and expressed as p values. Mann-Whitney U-test was used to compare TGF-β levels in both colostrum and mature milk and TGF-β ratio (1-month milk/colostrum) between eczema and control group. Changes in TGF-β levels from colostrum to mature milk was assessed with the Wilcoxon signed rank test. Adjusted logistic regression analyses were conducted to evaluate the association between eczema and TGF-β ratio. The TGF-β ratio was categorized into tertile as low, medium, or high levels.

For all analyses, p < 0.05 was considered statistically significant. Statistical analysis was performed with SPSS software ver. 11.0 (SPSS INC., Chicago, IL, USA).

RESULTS

Study Subjects
Fifty-one infants developed eczema at 6 months of age. Because of the lack of mother’s milk, 8 infants with eczema were excluded from the study, leaving 43 subjects for final analysis. As controls, 53 children without eczema were randomly selected. Table 1 shows the characteristics of the participants. The only difference between the two groups was gender proportion, with a higher number of girls in the control group.

| Characteristic of the participants. | Eczema group (n = 43) | Control group (n = 53) | p-value |
|------------------------------------|----------------------|-----------------------|---------|
| Sex (boy: girl)                    | 30:13                | 21:32                 | <0.05   |
| Father allergy                     | 26                   | 40                    | 0.12    |
| Mother allergy                     | 28                   | 38                    | 0.49    |
| Mother atopic dermatitis           | 11                   | 12                    | 0.74    |
| Mother smoking                     | 2                    | 5                     | 0.37    |
| Pet                                | 11                   | 16                    | 0.62    |
| Feeding methods                    |                       |                       |         |
| Mixed                              | 22                   | 30                    | 0.59    |
| Breast feeding                     |                       |                       |         |
| 0–1 months                         | 6                    | 3                     | 0.15    |
| 1–5 months                         | 4                    | 4                     | 0.52    |
| ≥ 6 months                         | 11                   | 16                    | 0.62    |
TGF-β Levels in Colostrum and Infant Eczema

In colostrum, TGF-β1 was undetectable in 29 samples of the control group, but only in 6 samples from the eczema group. TGF-β2 was detectable in all 96 samples. Undetectable TGF-β1 level in colostrum was set at 78 pg/mL.

Figure 1 shows the comparison of TGF-β1 and TGF-β2 levels in colostrum in both groups. TGF-β1 levels were significantly higher in the eczema group with a median 878.8 pg/mL (range 78–2,921 pg/mL) than that of control group (median: 78 pg/ml, range 78–5,538 pg/ml, p < 0.01, Figure 1A), while the levels of TGF-β2 was not significantly different between eczema group and control group (median: 4,129 pg/mL, range 1,175–31,900 pg/mL; and median: 4,977 pg/mL, range 721.2–26,260 pg/mL, respectively, p = 0.92, Figure 1B).

TGF-β Levels in 1-Month Milk and Infant Eczema

In 1-month milk, TGF-β1 were undetectable in 19 samples from the control group and 24 in the eczema group. TGF-β2 were undetectable only in 4 samples of the eczema group. Undetectable levels of either TGF-β1 in 1-month milk was also set at 78 pg/mL. Undetectable levels of TGF-β2 in 1-month milk was also set at 121.9 pg/mL.

Figure 2 shows the comparison of TGF-β1 and TGF-β2 levels in 1-month milk in both groups. In contrast to colostrum, TGF-β1 levels in the eczema group was lower than those in the control group (median: 78 pg/mL, range 78–1,768 pg/mL; and median: 311.2 pg/mL, range 78–3,903 pg/mL, respectively, p < 0.01, Figure 2A), while there was no significant difference in the TGF-β2 levels between eczema group and control group (median: 1,692 pg/mL, range 121.9–12,370 pg/mL; and median 1,550 pg/mL, range 255.2–8,273 pg/mL, respectively, p = 0.65, Figure 2B).

TGF-β Levels Ratio and Eczema in Infants

Figure 3 shows the change in TGF-β levels in colostrum vs. 1-month milk in both groups. TGF-β1 concentration did not decrease in the control group (p = 0.21); however, there was a significant reduction in the eczema group (p < 0.01, Figure 3A). TGF-β2 concentration significantly decreased in both groups (p < 0.01, Figure 3B).

TGF-β1 ratio (1-month milk/colostrum) was lower in the eczema group than in the control group (p < 0.01, Figure 4A).
Morita et al. Eczema and Breast Milk TGF-β

FIGURE 3 | Individual values of TGF-β1 (A) and TGF-β2 (B) in colostrum and 1-month milk in eczema group (43 subjects) and control group (53 subjects).

FIGURE 4 | TGF-β1 ratio (1-month milk/colostrum) (A) and TGF-β2 ratio (1-month milk/colostrum) (B) in eczema group (43 subjects) and control group (53 subjects).

The TGF-β2 ratio was not statistically different between the two groups ($p = 0.33$, Figure 4B).

**Multivariable Analysis**

Table 2 describes the results of multivariate analysis with logistic regression. The risk of eczema was inversely related to TGF-β1 ratio.

**Effect of Maternal Allergic History on TGF-β Levels in Breast Milk**

We also compared TGF-β1 and TGF-β2 levels in both colostrum and 1-month milk in allergic mothers. The levels of TGF-β1 and TGF-β2 in colostrum were not significantly different between allergic mothers (median: 511.1 pg/mL, range 78–5,538 pg/mL; and median: 4,826 pg/mL, range 721.2–31,900 pg/mL, respectively, $p = 0.56$), and in non-allergic mothers (median: 511.1 pg/mL, range 78–2,799 pg/mL; and median: 4,553 pg/mL, range 1,402–16,650 pg/mL, respectively, $p = 0.55$), neither were their concentrations in 1-month milk in allergic (median: 169.1 pg/mL, range 78–3,903 pg/mL; and median: 1,678 pg/mL, range 121.9–12,370 pg/mL, respectively, $p = 0.4$) and non-allergic mothers (median: 183.4 pg/mL, range 78–3,119 pg/mL; and median: 1,129 pg/mL, range 121.9–7,852, respectively, $p = 0.28$).

**TABLE 2** | Multiple regression analysis for the effect of TGF-β ratio on eczema.

| Factor                        | Adjusted odds ratio | 95% CI      | $p$-value |
|-------------------------------|--------------------|------------|-----------|
| Sex (Male)                    | 2.084              | 0.774 ~ 5.610 | 0.146     |
| Mother allergy                | 0.560              | 0.185 ~ 1.699 | 0.306     |
| Breast feeding by 1 month     | 1.203              | 0.444 ~ 3.288 | 0.711     |
| **TGF-β1 RATIO (1-MONTH/COLOSTRUM)** |                    |            |           |
| Low                           | 0.0267–0.224       | 1          |           |
| Middle                       | 0.229–1            | 0.161      | 0.049 ~ 0.534 | <0.01 |
| High                         | 1.013–49.588       | 0.035      | 0.006 ~ 0.188 | <0.01 |
| **TGF-β2 RATIO (1-MONTH/COLOSTRUM)** |                    |            |           |
| Low                           | 0.0182–0.214       | 1          |           |
| Middle                       | 0.231–0.464        | 0.848      | 0.250 ~ 2.878 | 0.792 |
| High                         | 0.473–3.731        | 2.959      | 0.702 ~ 12.467 | 0.139 |

Logistic regression models adjusted for sex, maternal history of allergies, breast feeding by 1 month and TGF-β ratio.
DISCUSSION

We demonstrated that principally a lower TGF-β1 ratio (1-month milk/colostrum) was related to later eczema in infants.

Reports on the relationship between TGF-β in breast milk and onset of allergic diseases are controversial. Some studies have reported that neither TGF-β1 nor TGF-β2 was associated with the onset of allergic disease (7–9, 11), while others have demonstrated such an association (12–14). In the present study, we found a significant relationship between TGF-β1 levels in breast milk and the development of eczema. In the eczema group, the TGF-β1 concentration was higher in colostrum, but lower in 1-month milk. In contrast with previous reports, we measured TGF-β at multiple time points and assessed the TGF-β ratio.

The higher dose of TGF-β1 (long breast feeding and medium-high TGF-β1) in breast milk were shown to have a protective effect against wheezing (12); although the outcome was different, we saw a similar pattern with eczema in our study. Riggotti et al. reported that TGF-β1 was significantly higher in the mature milk of non-allergic mothers, and infants fed with this TGF-β1-rich breast milk had less risk of developing atopic diseases (15), further emphasizing the protective effects of this cytokine against eczema. Their results might be due to genetic causes as they had grouped their cohort based on the mother’s allergic background. Levels of TGF-β1 reportedly decreases from colostrum to mature milk in urban mothers but not in rural mothers (16). These findings and our results suggest that a significant decrease in TGF-β1 in colostrum to mature milk is associated with later allergic disease. Lower levels of TGF-β2 in colostrum were observed with Lactobacillus reuteri supplementation during pregnancy, leading to less sensitization in children of those mothers during the first 2 years of life (13). Nonetheless, higher levels of TGF-β2 in breast milk were reportedly related to higher risk of eczema (14). In our study, both TGF-β2 levels and 1-month/colostrum ratio for TGF-β2 were not different between eczema group and control group.

The factors influencing the levels of TGF-β in breast milk are not well known. TGF-β levels in breast milk differed between countries (17, 18), and even races in the same country (19, 20). Similar to our results, no difference was observed in the allergic history of mothers (21). There have been conflicting results between the supplementation of probiotics during pregnancy and TGF-β1 levels, with a previous study reporting a significant increase in TGF-β1 levels (22); although, other investigations did not support such a result (23–27). Further studies are needed to clarify the factors influencing the levels of TGF-β in breast milk.

As for the limitations of this study; first, in our recruitment, we had more boys in the eczema group. And second, we could not evaluate long-term outcomes. Nonetheless, the present study suggests that TGF-β1 levels in breast milk are related to the occurrence of eczema later in life.

In conclusion, the present investigation suggested that a higher 1-month/colostrum ratio for TGF-β1 is associated with a more consistent concentration or an increase of TGF-β1 across the first month, which has a protective effect in reducing the risk of eczema. Additional studies are needed to evaluate the relationship between TGF-β levels in breast milk and the development of allergic disease. Identifying factors that increase TGF-β1 levels in breast milk may contribute to preventing allergic diseases.

AUTHOR CONTRIBUTIONS

YM wrote this manuscript and did statistical analysis. EC-A wrote this manuscript. FY, TN and NoK provided critical advice. YK and NaK conducted study. HO, MK and EM measured TGF-β. NS conducted study and wrote this manuscript.

FUNDING

This study was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, Technology, the ministry of Health Labor and Welfare, Japan and the Japan Agency for Medical Research and Development (AMED)—Innovative Advanced Research and Development (AMED-CREST).

ACKNOWLEDGMENTS

We express our gratitude to all the children and families that participated in our study.

REFERENCES

1. Hanson LA. Session 1: feeding and infant development breast-feeding and immune function. Proc Nutr Soc. (2007) 66:384–96. doi: 10.1017/S0029665107005654
2. Ando T, Hatushika K, Wako M, Ohba T, Koyama K, Ohnuma Y, et al. Orally administered TGF-beta is biologically active in the intestinal mucosa and enhances oral tolerance. J Allergy Clin Immunol. (2007) 120:916–23. doi: 10.1016/j.jaci.2007.05.023
3. Shiou SR, Yu Y, Guo Y, Westerhoff M, Lu L, Petrof EO, et al. Oral administration of transforming growth Factor-β1 (TGF-β1) protects the immature gut from injury via smad-proteindependent suppression of epithelial nuclear factor-kb (NF-kB) signaling and proinflammatory cytokine production. J Biol Chem. (2013) 288:34757–66. doi: 10.1074/jbc.M113.503946
4. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development (1997) 124:2659–70. doi: 10.1086/C1M.2009.n.003.Novel
5. Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, et al. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet. (1995) 11:415–21. doi: 10.1038/ng1295–1415
6. Oddy WH, Rosales F. A systematic review of the importance of milk TGF-beta on immunological outcomes in the infant and young child. Pediatr Allergy Immunol. (2010) 21:47–59. doi: 10.1111/j.1399-3038.2009.00913.x
7. Savilahti E, Siltanen M, Kajosaari M, Vaarala O, Saarinen KM. IgA antibodies, TGF-beta1 and -beta2, and soluble CD14 in the colostrum and development of atopy by age 4. Pediatr Res. (2005) 58:1300–5. doi: 10.1203/01.pdr.0000183784.87452.c6
8. Snijders BEP, Damoiseaux JGMC, Penders J, Kummeling I, Stelma FF, van Ree R, et al. Cytokines and soluble CD14 in breast milk in relation with atopic manifestations in mother and infant (KOALA Study). *Clin Exp Allergy* (2006) **36**:1609–15. doi: 10.1111/j.1365-2222.2006.02613.x

9. Ismail IH, Liciardi P V, Oppedalsø F, Boyle RJ, Tang MLK, Relationship between breast milk scCD14, TGF-β1 and total IgA in the first month and development of eczema during infancy. *Pediatr Allergy Immunol.* (2013) **24**:352–60. doi: 10.1111/pai.12075

10. Ozawa N, Shimojo N, Suzuki Y, Ochiai S, Nakano T, Morita Y, et al. Maternal intake of natto, a Japan’s traditional fermented soybean food, during pregnancy and the risk of eczema in Japanese babies. *Allergol Int.* (2014) **63**:261–6. doi: 10.2332/allergolint.13-OA-0613

11. Orivuori L, Loss G, Roduit C, Dalphin JC, Depner M, Genuneit J, et al. Soluble immunoglobulin A in breast milk is inversely associated with atopic dermatitis at early age: the PASTURE cohort study. *Clin Exp Allergy* (2014) **44**:102–12. doi: 10.1111/cea.12199

12. Oddy WH, Halonen M, Martinez FD, Lohman JC, Stern DA, Kurzius-Spen cer M, et al. TGF-beta in human milk is associated with wheeze in infancy. *J Allergy Clin Immunol.* (2003) **112**:723–8. doi: 10.1016/S0091-6749(03)70819-5

13. Böttcher MF, Abrahamsson TR, Fredriksson M, Jakobsson T, Björkstén B. Low breast milk TGF-beta2 is induced by *Lactobacillus reuteri* supplementation and associates with reduced risk of sensitization during infancy. *Pediatr Allergy Immunol.* (2008) **19**:497–504. doi: 10.1111/j.1399-3038.2007.00687.x

14. Munblit D, Treneva M, Peroni DG, Colicino S, Chow LY, Dissanayake S, et al. Immune components in human milk are associated with early immunological health outcomes: a prospective three-country analysis. *Nutrients* (2017) **9**:1–14. doi: 10.3390/nu9090532

15. Rigotti E, Piccentini GL, Ress M, Pigozzi R, Boner AL, Peroni DG, Transferring growth factor-beta and interleukin-10 in breast milk and development of atopic diseases in infants. *Clin Exp Allergy* (2006) **36**:614–8. doi: 10.1111/j.1365-2222.2006.02483.x

16. Peroni DG, Pescollderung L, Piccentini GL, Rigotti E, Maselli M, Watschinger K, et al. Maternal country of birth and previous pregnancies are associated with immune regulatory cytokines in the milk of lactating women from farming and urban environments. *Pediatr Allergy Immunol.* (2010) **21**:977–82. doi: 10.1111/j.1399-3038.2010.00995.x

17. Tomić S, Johansson G, Voer T, Björkstén B, Böttcher MF, Jennmalm MC. Breast milk cytokine and IgA composition differ in estonian and swedish mothers-relationship to microbial pressure and infant allergy. *Pediatr Res.* (2010) **68**:330–4. doi: 10.1203/PDR.0b013e3181ee4094

18. Aihara Y, Oh-oka K, Kondo N, Sharma J, Ishimaru K, Hara M, et al. Comparison of colostrum TGF-β2 levels between lactating women in Japan and Nepal. *Asian Pac J Allergy Immunol.* (2014) **32**:178–84. doi: 10.1016/S0219-8249(14)60052-2

19. Amoudruz P, Holmlund U, Schölln J, Sverremark-Ekström E, Montgomery SM. Maternal country of birth and previous pregnancies are associated with breast milk characteristics. *Pediatr Allergy Immunol.* (2009) **20**:19–29. doi: 10.1111/j.1399-3038.2008.00754.x

20. Joseph CLM, Havstad S, Bobbitt K, Woodcroft K, Zoratti EM, Nageotte C, et al. Transforming growth factor beta (TGFβ1) in breast milk and indicators of infant atopy in a birth cohort. *Pediatr Allergy Immunol.* (2014) **25**:257–63. doi: 10.1111/pai.12205

21. Prokesová L, Lodinová-Zádňáková R, Žiška J, Kocoureková J, Novotná O, Petrášková P, et al. Cytokine levels in healthy and allergic mothers and their children during the first year of life. *Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol.* (2006) **17**:175–83. doi: 10.1111/j.1399-3038.2006.00395.x

22. Prescott SL, Wickens K, Westcott L, Jung W, Currie H, Black PN, et al. Supplementation with *Lactobacillus rhamnosus* or *Bifidobacterium lactis* probiotics in pregnancy increases cord blood interferon-gamma and breast milk transforming growth factor-beta and immunoglobin A detection. *Clin Exp Allergy* (2008) **38**:1606–14. doi: 10.1111/j.1365-2222.2008.03061.x

23. Huurre A, Laitinen K, Rautava S, Korkeamäki M, Isolauri E. Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization: a double-blind placebo-controlled study. *Clin Exp Allergy* (2008) **38**:1342–8. doi: 10.1111/j.1365-2222.2008.03008.x

24. Boyle RJ, Ismail IH, Kivivuori S, Liciardi PV, Robins-Browne RM, Mah LJ, et al. *Lactobacillus GG* treatment during pregnancy for the prevention of eczema: a randomized controlled trial. *Allergy* (2011) **66**:509–16. doi: 10.1111/j.1399-3038.2010.02507.x

25. Kuitunen M, Kukkonen AK, Savilahit E. Impact of maternal allergy and use of probiotics during pregnancy on breast milk cytokines and food antibodies and development of allergy in children until 5 years. *Int Arch Allergy Immunol.* (2012) **159**:162–70. doi: 10.1159/000336157

26. Simpson MR, Rø ADB, Grimstad Ø, Johnsen R, Storre O, Olsen T. Atopic dermatitis prevention in children following maternal probiotic supplementation does not appear to be mediated by breast milk TSLP or TGF-β. *Clin Transl Allergy* (2016) **6**:27. doi: 10.1186/s13601-016-0119-6

27. Wickens K, Barthow C, Mitchell EA, Stanley TV, Purdie G, Rowden J, et al. Maternal supplementation alone with *Lactobacillus rhamnosus* HN001 during pregnancy and breastfeeding does not reduce infant eczema. *Pediatr Allergy Immunol* (2018) **29**:296–302. doi: 10.1111/pai.12874

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Morita, Campos-Alberto, Yamaide, Nakano, Ohnise, Kawamoto, Kawamoto, Matsui, Kondo, Kohno and Shimojo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.